S Popat
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Mazières J, Rothschild S, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten R, Wakelee H, Camidge D, Zalcman G, Novello S, Ou S, Milia J, Zhu V, Sabari J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L, Thai A, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng T, Gounant V, Popat S, Diebold J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019
May 24, 2019Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
May 24, 2019Ann Oncol 2019
Mazières J, Rothschild S I, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten R D, Wakelee H, Camidge D R, Zalcman G, Novello S, Ou S I, Milia J, Zhu V W, Sabari J, Drilon A, Lusque A, Mhanna L, Cortot A B, Mezquita L, Thai A A, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh Martin, Ng T L, Gounant V, Popat S, Diebold J, Gautschi O
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi99-105.
Jun 27, 2013Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Jun 27, 2013Ann Oncol 2013; 24 Suppl 6:vi99-105
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group